HomeCompareNRBO vs NNN

NRBO vs NNN: Dividend Comparison 2026

NRBO yields 84.75% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NRBO wins by $2.02M in total portfolio value
10 years
NRBO
NRBO
● Live price
84.75%
Share price
$2.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.05M
Annual income
$615,863.14
Full NRBO calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — NRBO vs NNN

📍 NRBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNRBONNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NRBO + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NRBO pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NRBO
Annual income on $10K today (after 15% tax)
$7,203.39/yr
After 10yr DRIP, annual income (after tax)
$523,483.67/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, NRBO beats the other by $521,254.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NRBO + NNN for your $10,000?

NRBO: 50%NNN: 50%
100% NNN50/50100% NRBO
Portfolio after 10yr
$1.04M
Annual income
$309,242.91/yr
Blended yield
29.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

NRBO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-20.1
Piotroski
0/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NRBO buys
0
NNN buys
0
No recent congressional trades found for NRBO or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNRBONNN
Forward yield84.75%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$2.05M$25.5K
Annual income after 10y$615,863.14$2,622.67
Total dividends collected$1.79M$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: NRBO vs NNN ($10,000, DRIP)

YearNRBO PortfolioNRBO Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$19,175$8,474.58$10,735$614.96+$8.4KNRBO
2$35,703$15,186.58$11,572$708.43+$24.1KNRBO
3$64,630$26,427.72$12,531$819.53+$52.1KNRBO
4$113,864$44,709.84$13,633$952.29+$100.2KNRBO
5$195,450$73,615.70$14,909$1,111.84+$180.5KNRBO
6$327,228$118,096.19$16,392$1,304.77+$310.8KNRBO
7$534,919$184,784.73$18,129$1,539.52+$516.8KNRBO
8$854,669$282,305.61$20,173$1,827.08+$834.5KNRBO
9$1,336,042$421,546.65$22,597$2,181.81+$1.31MNRBO
10$2,045,428$615,863.14$25,491$2,622.67+$2.02MNRBO

NRBO vs NNN: Complete Analysis 2026

NRBOStock

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Full NRBO Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this NRBO vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NRBO vs SCHDNRBO vs JEPINRBO vs ONRBO vs KONRBO vs MAINNRBO vs ADCNRBO vs EPRTNRBO vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.